Abstracts tagged "Vasculitis"

Abstract Number: 1438 • ACR Convergence 2020
Rituximab Immunogenicity in ANCA-associated Vasculitis (RITUXIMAV)
Jason Springer¹ and Ryan Funk², ¹University of Kansas Medical Center, Overland Park, KS, ²UNIVERSITY OF KANSAS, Kansas City, KS
Background/Purpose: Rituximab (RTX), an anti-CD20 chimeric monoclonal antibody, has been shown to be an effective maintenance therapy for granulomatosis with polyangitiis (GPA) and microscopic polyangiitis…
Abstract Number: 1931 • ACR Convergence 2020
Effect of Cumulative Glucocorticoid Dose and Inflammation on Weight Change During Treatment of Giant Cell Arteritis
Naomi Serling-Boyd¹, Xiaoqing Fu², Yuqing Zhang³, Sebastian Unizony¹, Zachary Wallace⁴, Hyon Choi⁵ and John H. Stone⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Quincy, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Giant cell arteritis (GCA) is a form of large vessel vasculitis that requires treatment with high-dose, long-term glucocorticoids (GC). Weight gain, among other side-effects…
Abstract Number: 0409 • ACR Convergence 2020
Clinical Characteristics, Brain MRI Findings, and Diagnostic Approach of the Central Nervous System Vasculitis by Affected Vessel Size
Takashi Shimoyama¹, Ken Uchino², Leonard Calabrese³ and Rula Hajj-ali³, ¹Nippon Medical School, Nippon, Japan, ²Cleveland Clinic, Cleveland, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Diagnosis of the central nervous system vasculitis (CNS-V) is made on the basis of image findings or brain biopsy. Recently, two diﬀerent subtypes of…
Abstract Number: 0518 • ACR Convergence 2020
The Impact of Large Vessel Vasculitis of the Axillary Artery on Cumulative Glucocorticoid Dose and Relapse Rate in Giant Cell Arteritis
Philipp Bosch¹, Christian Dejaco², Wolfgang Schmidt³, Andreas Krause³, Kenny-Davis Schlüter³, Gudrun Pregartner⁴ and Valentin Schaefer⁵, ¹Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, ²Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria and Rheumatology Service, Hospital of Bruneck, Bruneck, Italy, Bruneck, Italy, ³Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ⁴Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria, Graz, Austria, ⁵Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Prognostic markers for clinical outcomes in giant cell arteritis (GCA) are urgently needed. While large vessel GCA (LV-GCA) has been associated with higher glucocorticoid…
Abstract Number: 1439 • ACR Convergence 2020
Proteinase 3-Reactive B Cell Pool Restructuring After Rituximab and Risk of Relapse in Severe PR3-ANCA-Associated Vasculitis
Alvise Berti¹, Sophie Hillion², Marta Casal Moura¹, Amber Hummel¹, Eva Carmona¹, Tobias Peikert¹, Carol Langford³, Peter A. Merkel⁴, Paul Monach⁵, Philip Seo⁶, Robert Spiera⁷, Eugene St Clair⁸, Fernando C. Fervenza¹, Kristina Harris⁹, John H. Stone¹⁰, Jacques-Olivier Pers¹¹, Ulrich Specks¹ and Divi Cornec¹², ¹Mayo Clinic, Rochester, MN, ²Brest University, Brest, Bretagne, France, ³Cleveland Clinic, Moreland Hills, OH, ⁴Division of Rheumatology University of Pennsylvania, Philadelphia, PA, ⁵Brigham and Women's, Boston, ⁶Johns Hopkins University, Baltimore, MD, ⁷Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, ⁸Duke University, Durham, NC, ⁹Immune Tolerance Network, Bethesda, MD, ¹⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹¹University of Brest, Brest, France, ¹²Rheumatology Department, Brest University Hospital, Brest, France
Background/Purpose: In ANCA-associated vasculitis (AAV) B cells play a central pathogenic role and are instrumental for the production of ANCA, which are thought to mediate…
Abstract Number: 1933 • ACR Convergence 2020
Small Vessel Vasculitis Surrounding a Preserved Temporal Artery: Search for Tissue Biomarkers with Potential Diagnostic Value
Georgina Espígol-Frigolé¹, Roser Alba-Rovira², Salvador Naranjo-Suárez³, Magda Terenas⁴, Sergio Prieto-González¹, Marc Corbera-Bellalta³, Javier Marco-Hernández⁴, Marco A. Alba¹, Farah Kamberovic³, Roberto Ríos-Garcés¹, Jose Hernández-Rodríguez¹ and Maria C. Cid¹, ¹Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, IRB-CELLEX. Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain, Barcelona, ³IDIBAPS, Barcelona, Spain, ⁴Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose: Systemic vasculitides are complex and heterogeneous diseases with overlapping features that frequently pose a diagnostic challenge to clinicians. The temporal artery biopsy (TAB) is…
Abstract Number: 0410 • ACR Convergence 2020
Exploring Gene Expression Profile of Primary Central Nervous System Vasculitis
Carlo Salvarani¹, Robert Brown², Jonas Paludo², Stefania Croci³, Stephen Ansell⁴, Caterina Giannini², Joseph Parisi², Kenneth Warrington² and Gene Hunder², ¹Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ²Mayo Clinic, Rochester, MN, ³Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Mayo Clinic, Rochester
Background/Purpose: Primary CNS vasculitis (PCNSV) is an uncommon and poorly understood disease that affects the brain and spinal cord. It includes heterogeneous histopathological patterns, clinical…
Abstract Number: 0937 • ACR Convergence 2020
Late Cardiovascular Outcomes in Children with Kawasaki Disease: A Population-based Cohort Study
Cal Robinson¹, Rahul Chanchlani¹, Anastasia Gayowsky², Sandeep Brar³, Elizabeth Darling⁴, Catherine Demers⁴, Tapas Mondal¹, Rulan Parekh⁵, Hsien Seow⁴ and Michelle Batthish¹, ¹McMaster Children's Hospital, Hamilton, ON, Canada, ²ICES McMaster, Hamilton, ON, Canada, ³University of California, San Fransisco, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Toronto, Toronto, Canada
Background/Purpose: Kawasaki disease (KD) is a common childhood vasculitis associated with coronary artery aneurysms (CAA). Based on our recent work, the incidence of KD has…
Abstract Number: 1539 • ACR Convergence 2020
Diagnostic Value of Ultrasound Halo Count and Halo Score in Giant Cell Arteritis: A Retrospective Study from Routine Care
Juan Molina Collada¹, Julia Martínez-Barrio², Belen Serrano-Benavente¹, Isabel Castrejon Fernandez³, Liz Caballero Motta¹, Laura Trives Folguera¹ and Jose Maria Alvaro-Gracia⁴, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, ³Hospital General Universitario Gregorio Marañón, Chicago, IL, ⁴CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Ultrasound (US) of temporal (TA) and axillary arteries is recommended as the first imaging modality in patients with suspected predominantly cranial giant cell arteritis…
Abstract Number: 1934 • ACR Convergence 2020
What Is the Significance of Periarterial Temporal Small Vessel Inflammation (SVI) on Temporal Artery Biopsy (TAB) in the Diagnosis of Vasculitis? A Systematic Review and Meta-analysis
Elise Belilos¹, Steven Carsons² and Sonya Mehta¹, ¹NYU Winthrop Hospital, Mineola, NY, ²NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Isolated inflammation of small vessels including capillaries, venules and arterioles surrounding a normal temporal artery (SVI) in patients suspected of having giant cell arteritis…
Abstract Number: 0411 • ACR Convergence 2020
Serial Vessel Wall Enhancement Change on High-Resolution MRI Vessel Wall Imaging in Primary Central Nervous System Vasculitis
Takashi Shimoyama¹, Ken Uchino², Leonard Calabrese² and Rula Hajj-ali², ¹Nippon Medical School, Nippon, Japan, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: High-resolution vessel wall imaging (HR-VWI) is emerging as a tool of notable utility in the diagnosis of central nervous system vasculitis (CNS-V). However, little…
Abstract Number: 1132 • ACR Convergence 2020
Reliability of Virtual Sources of Education for Patients with Vasculitis
Patil Injean¹, Kathleena D'Anna², Lorena Salto³ and Mehrnaz Hojjati³, ¹Loma Linda University Medical Center, Redlands, CA, ²Loma Linda University Medical Center, Moreno Valley, CA, ³Loma Linda University, Loma Linda
Background/Purpose: Vasculitides are defined as inflammation of the vessel wall of different organ systems with reactive damage of mural structures. Patient education in understanding the…
Abstract Number: 1554 • ACR Convergence 2020
Response to Tocilizumab in Large Vessel Vasculitis According to the Extent of Baseline 18F-FDG Vascular Uptake
Lara Sanchez-Bilbao¹, Diana Prieto-Peña², Inigo Gonzalez-Mazon³, David Martinez-Lopez⁴, Monica Calderon-Goercke⁵, Isabel Martínez-Rodríguez⁵, Ignacio Banzo⁵, Miguel Ángel González-Gay⁶ and Ricardo Blanco¹, ¹Hospital Universitario Marques de Valdecilla, Santander, Spain, ²Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁶Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: 18F-fluodeoxyglucose positron emission tomography (18F-FDG PET/CT) is useful to establish the presence and extent of large vessel vasculitis (LVV). Tocilizumab (TCZ) has shown efficacy…
Abstract Number: 1938 • ACR Convergence 2020
Risk for Vision Loss and Relapse in Patients with Giant Cell Arteritis
Anne Bull Haaversen¹ and Andreas Diamantopoulos², ¹Martina Hansens Hospital, Hosle, Norway, ²Martina Hansens Hospital, Baerum, Norway
Background/Purpose: Giant cell arteritis (GCA) involves both the cranial and large vessels. Studies have shown that while the vision loss rates are higher, the relapse…
Abstract Number: 0412 • ACR Convergence 2020
2019 Novel Coronavirus Disease (COVID-19) in Patients with Large-Vessels Vasculitis: Single-centre Experience in Paris
Chloé Comarmond¹, Mathilde Leclercq¹, Gaëlle Leroux², Cindy Marques², Alexandre Le Joncour³, Fanny Domont², Céline Hatte¹, Ségolène Toquet¹, Perrine Guillaume-Jugnot¹, Anne-Claire Desbois¹, Mathieu Vautier¹, Aude Rigolet¹, Yves Allenbach⁴, Olivier Benveniste⁵, David Saadoun² and Patrice Cacoub², ¹Assistance Publique des Hopitaux de Paris, Paris, France, ²AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, Paris, France, ³APHP, paris, France, ⁴Sorbonne Université, Paris, Ile-de-France, France, ⁵Sorbonne Université, paris, France
Background/Purpose: Advanced age and cardiovascular diseases are recognized as major comorbidities associated with severe forms of coronavirus disease 2019 (COVID-19) caused by the severe acute…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].